Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum β-lactamase-producing Escherichia coli bacteraemia

Scandinavian Journal of Infectious Diseases

Volumn 46, Issue 11, 2014, Pages 753-762

  Van Aken, Stefanie ^a   Lund, Nathalie ^a   Ahl, Jonas ^b   Odenholt, Inga ^b   Tham, Johan ^b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Antibiotic resistance; Bacteraemia bloodstream infection; Empirical antibiotic treatment; ESBL; Escherichia coli

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFOTAXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TOBRAMYCIN; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ABDOMINAL INFECTION; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; COMMUNITY ACQUIRED INFECTION; CONTROLLED STUDY; ESCHERICHIA COLI INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREVALENCE; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; URINARY TRACT INFECTION; ANTIBIOTIC RESISTANCE; BIOSYNTHESIS; CASE CONTROL STUDY; CATHETERIZATION; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; MICROBIOLOGY; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CASE-CONTROL STUDIES; CATHETERIZATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84912011262     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2014.937454     Document Type: Article

References (40)

1. Peralta G, Sanchez MB, Garrido JC, De Benito I, Cano ME , Martinez-Martinez L, et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 2007;60:855-63
2. Rodriguez-Bano J, Picon E, Gijon P, Hernandez J R , Ruiz M, Pena C, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factorSand prognosis. Clin Infect Dis 2010;50:40-8
3. Tumbarello M, Spanu T, D i Bidino R, Marchetti M , Ruggeri M, Trecarichi EM, et al. Costs of bloodstream infections caused by Escherichia coli and Influence of extendedspectrum- beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 2010;54 : 4085-91
4. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E , Leibovici L. Systematic revieWand meta-analysis of the effi - CacYof appropriate empiriCantibiotic therapy for sepsis. Antimicrob Agents Chemother 2010;54:4851-63
5. Hawkey PM, Jones AM. The changing epidemiologYof resistance. J Antimicrob Chemother 2009;64(Suppl 1) : i3-10
6. Livermore DM. F ourteen years in resistance. I nt J Antimicrob Agents 2012;9:283-94
7. Paterson D L, Bonomo RA. Extended-spectrum betalactamases: a clinical update. Clin Microbiol Rev 2005;18:657-86
8. Pitout J D, Laupland K B. Extended-spectrum betalactamase- producing Enterobacteriaceae: an emerging public- health concern. Lancet Infect Dis 2008;8:159-66
9. Rodriguez-Bano J, Picon E, Gijon P, Hernandez J R , Cisneros JM, Pena C, et al. Risk factorSand prognosis of nosocomial bloodstream infections caused by extendedspectrum- beta-lactamase-producing Escherichia coli. J Clin Microbiol 2010;48:1726-31
10. Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD , Quentin C, Calbo ES, et al. Amultinational surveYof risk factors for infection with extended-spectrum beta-lactamaseproducing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009;49:682-90
11. Peralta G, Lamelo M, Alvarez-Garcia P, Velasco M , Delgado A, Horcajada JP, et al. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. Amulticentric cohort study. BMC Infect Dis 2012;12:245
12. Tumbarello M, Sali M, Trecarichi E M, Leone F, Rossi M , Fiori B, et al. Bloodstream infections caused by extendedspectrum- beta-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 2008;52:3244-52
13. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi E M , Posteraro B, Fiori B, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrumbeta- lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007;51:1987-94
14. Rottier W C, Ammerlaan HS, Bonten MJ. Effects of confounderSand intermediates on the association of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae and patient outcome: Ameta-analysis. J Antimicrob Chemother 2012;67:1311-20
15. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extendedspectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrugresistant Pseudomonas aeruginosa. Mayo Clin Proc 2011;86:250-9
16. Nasa P, Juneja D, Singh O, Dang R, Singh A. An observational studYon bloodstream extended-spectrum betalactamase infection in critical care unit: incidence, risk factorSand its impact on outcome. Eur J Intern Med;23:192-5
17. Martinez JA, Cobos-Trigueros N, Soriano A, AlmelAm, OrtegAm, Marco F, et al. Influence of empiric therapy with a beta-lactaMalone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother 2010;54:3590-6
18. Rodriguez-Bano J, Lopez-Prieto M D, Portillo MM , Retamar P, Natera C, Nuno E, et al. Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals. Clin MicrobioLinfect 2010;16:1408-13
19. de Kraker M E, Wolkewitz M, Davey P G, Koller W, Berger J , Nagler J, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2011;66:398-407
20. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic revieWand meta-analysis. J Antimicrob Chemother 2007;60:913-20
21. Marchaim D, Gottesman T, Schwartz O, Korem M, Maor Y , Rahav G, et al. National multicenter studYof predictorSand outcomes of bacteremiAupon hospital admission caused by Enterobacteriaceae producing extended-spectrum betalactamases. Antimicrob Agents Chemother 2010;54:5099-104
22. Kumar A, Roberts D, Wood K E, Light B, Parrillo J E, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survivaLin human septic shock. Crit Care Med 2006;34:1589-96
23. Micek S T, Welch E C, Khan J, Pervez M, Doherty J A , Reichley RM, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010;54:1742-8
24. Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M , Sanchez-Ortega I, et al. Bacteraemia due to multidrugresistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2011;66:657-63
25. Tumbarello M, Trecarichi E M, Bassetti M, De Rosa F G , Spanu T, Di Meco E, et al. Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother 2011;55 : 3485-90
26. Llewelyn MJ, Cohen J. Tracking the microbes in sepsis: adVancements in treatment bring challenges for microbiaLepidemiology. Clin Infect Dis 2007;44:1343-8
27. http://www.ecdc.europa.eu/en/healthtopics/antimicrobial- resistance/database/Pages/table-reports.aspx
28. Levy MM, Fink MP, Marshall JC, A braham E, Angus D , Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6
29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. Anew method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
30. Hall BG, Barlow M. Evolution of the serine beta-lactamases: past, present and future. Drug Resist Updat 2004;7 : 111-23
31. Referensmetodik fö r laboratoriediagnostik vid kliniskt mikrobiologiska laboratorier [database on the Internet] [cited 12 July 2012]. Available at: http://whttp://www.referensmetodik. smi.se/w/Referensmetodik:-Tarminfektioner
32. http://www.eucast.org/fi leadmin/src/media/PDFs/EUCAST- files/Consultation/EUCAST-guidelines-detection-of- resistance-mechanisms-121222
33. Hsieh C J, Shen Y H, Hwang K P. ClinicaLimplications, risk factorSand mortality following community-onset bacteremia caused by extended-spectrum beta-lactamase (ESBL) and non-ESBL producing Escherichia coli. J MicrobioLimmunoLinfect 2010;43:240-8
34. Tangden T, Cars O, Melhus A, Lowdin E. Foreign traveLis Amajor risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother 2010;54:3564-8
35. Tham J, Odenholt I, Walder M, Andersson L, Melander E. Risk factors for infections with extended-spectrum betalactamase- producing Escherichia coli in a countYof Southern Sweden. Infect Drug Resist 2013;6:93-7
36. Lee N Y, Huang W H, Tsui K C, Hsueh P R, Ko W C. Carbapenem therapy for bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Diagn MicrobioLinfect Dis 2011;70:150-3
37. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical anDeconomic impact of common multidrug-resistant gramnegative bacilli. Antimicrob Agents Chemother 2008;52 : 813-21
38. Harbarth S, Nobr V, Pittet D. DoeSantibiotic selection impact patient outcome?. Clin Infect Dis 2007;44:87-93
39. Marschall J, Agniel D, Fraser VJ, Doherty J, Warren DK. Gram-negative bacteraemia in non-ICU patients: factors associated with inadequate antibiotic therapy and impact on outcomes. J Antimicrob Chemother 2008;61:1376-83
40. Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I , Aldabo-Pallas T, Cayuela-Dominguez A, Marquez-Vacaro JA, et al. Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: Amatched cohort study. J Antimicrob Chemother 2008;61:436-41